CD79A and anaphylaxis: The IgE-mediated anaphylaxis characterized by flushing, facial swelling, dyspnea, hypotension, loss of consciousness, nausea, and vomiting has been reported in patients treated with IVIG, in individuals with IgA deficiency, or those with anti-IgA antibodies of the IgE type [43].